首页> 美国卫生研究院文献>Journal of Clinical Laboratory Analysis >Interleukin‐1‐β gene but not the interleukin‐1 receptor antagonist gene is associated with graves disease
【2h】

Interleukin‐1‐β gene but not the interleukin‐1 receptor antagonist gene is associated with graves disease

机译:白介素-1-β基因但白介素-1受体拮抗剂基因与坟墓病相关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Interleukin‐1 (IL‐1) is considered to be involved in the pathogenesis of Graves' disease. The aim of this study was to test whether the IL‐1‐β gene promoter region and exon 5 and IL‐1 receptor antagonist (IL‐1Ra) gene intron 2 polymorphisms could be useful genetic markers for susceptibility to Graves' disease. A normal control group of 163 healthy people and another group of 95 patients with Graves' disease were examined. Polymerase chain reaction (PCR) was used to analyze the variable number of tandem repeats (VNTRs) at intron 2 of the IL‐1Ra gene for the polymorphism. PCR‐based restriction analysis was done for the IL‐1‐β gene polymorphisms of the promoter region and exon 5 using endonucleases I and I, respectively. We found significantly increased frequencies of the C/C homozygous genotype (χ test, =0.038; odds ratio (OR)=2.558, 95% confidence interval (CI)=1.205–5.430) and the C allele (χ test, =0.011; OR=1.589, 95% CI=1.094–2.309) in the IL‐1‐β gene promoter (−511 C/T polymorphism) in Graves' disease patients compared to normal controls. There were no significant differences in polymorphisms of IL‐1‐β gene exon 5 and IL‐1Ra gene intron 2 between the patient and normal control groups. A subgroup analysis also demonstrated no association between the severity of the disease and any polymorphism of IL‐1‐related genes. We suggest that the IL‐1‐β gene promoter polymorphism can be used as a genetic marker for susceptibility to Graves' disease. It is worthwhile to study the cytokine genes further because of the association between cytokines and Graves' disease. J. Clin. Lab. Anal. 19:133–138, 2005. © 2005 Wiley‐Liss, Inc.
机译:白介素-1(IL-1)被认为与Graves病的发病机制有关。这项研究的目的是检验IL-1β基因启动子区域以及外显子5和IL-1受体拮抗剂(IL-1Ra)基因内含子2多态性是否可以用作Graves病易感性的遗传标记。检查了正常对照组的163名健康人和另一组95例的Graves病患者。聚合酶链反应(PCR)用于分析IL-1Ra基因内含子2上可变数目的串联重复序列(VNTR)的多态性。分别使用核酸内切酶I和I对启动子区域和外显子5的IL-1-β基因多态性进行了基于PCR的限制性分析。我们发现C / C纯合基因型(χ检验,= 0.038;比值比(OR)= 2.558,95%置信区间(CI)= 1.205-5.430)和C等位基因(χ检验,= 0.011;与正常对照组相比,格雷夫斯病患者的IL-1-β基因启动子(−511 C / T多态性)为OR = 1.589,95%CI = 1.094–2.309)。患者和正常对照组之间IL-1-β基因外显子5和IL-1Ra基因内含子2的多态性没有显着差异。亚组分析还表明,该疾病的严重程度与IL-1相关基因的任何多态性之间没有关联。我们建议将IL-1-β基因启动子多态性用作Graves病易感性的遗传标记。由于细胞因子与格雷夫斯病之间的关联,值得进一步研究细胞因子基因。 J.临床实验室肛门19:133–138,2005.©2005 Wiley-Liss,Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号